SCI Abstract

search
+
First, novel and paradigm-shifting
First, novel and paradigm-shifting
In delineating scientific findings, authors should avoid assertions of primacy and novelty, in favor of measured descripti...
A deep dive into transmissible cancer evolution in bivalve mollusks
A deep dive into transmissible cancer evolution in bivalve mollusks
Transmissible cancer affects marine bivalve mollusks worldwide, but how genetic mechanisms influence cancer evolution and ...
Myeloma evades T cell-engaging therapies
Myeloma evades T cell-engaging therapies
Chimeric antigen receptor T cells and T cell-redirecting bispecific antibody therapies are changing the landscape of myelo...
Endothelium directs fat remodeling in cachexia
Endothelium directs fat remodeling in cachexia
Certain cancers disrupt metabolism, leading to the wasting syndrome known as cachexia. How tumor-induced mediators of cach...
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation, trafficking and function...
Turning a failing PhD around
Turning a failing PhD around
Charles Swanton obtained a PhD from the Imperial Cancer Research Fund Laboratories (now the Francis Crick Institute) in 19...
Targeting network circuitry in glioma
Targeting network circuitry in glioma
The nervous system regulates cancer progression, and the importance of neuron–glioma communication in tumor growth i...
The never-abating excitement for targeted therapies
In combining technical innovation with foundational research, targeted therapies remain at the forefront of oncology drug ...
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia
Telomerase enables replicative immortality in most cancers including acute myeloid leukemia (AML). Imetelstat is a first-i...
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
Safely expanding indications for cellular therapies has been challenging given a lack of highly cancer-specific surface ma...
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma treated with regimens containing daratum...
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia
Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia
Despite recent advances in the treatment of acute myeloid leukemia (AML), there has been limited success in targeting surf...
An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma
An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma
In vitro-transcribed (IVT) mRNA has arisen as a rapid method for the production of nucleic acid drugs. Here, we have const...
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which...
Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma
Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma
In pancreatic ductal adenocarcinoma (PDAC), glutamine is a critical nutrient that drives a wide array of metabolic and bio...
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism
Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation and redox balance. Early attemp...
Immunotargeting of a recurrent AML-specific neoantigen
Immunotargeting of a recurrent AML-specific neoantigen
The development of immunotherapies for acute myeloid leukemia (AML) has been limited by a lack of known tumor-specific tar...
Centuries of genome instability and evolution in soft-shell clam, Mya arenaria, bivalve transmissible neoplasia
Centuries of genome instability and evolution in soft-shell clam, Mya arenaria, bivalve transmissible neoplasia
Transmissible cancers are infectious parasitic clones that metastasize to new hosts, living past the death of the founder ...
Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule
Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule
Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed b...
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Acute myeloid leukemia (AML), the most frequent leukemia in adults, is driven by recurrent somatically acquired genetic le...
Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
Ex vivo drug response profiling is a powerful tool to study genotype–drug response associations and is being explore...
Filippo Giancotti (1958–2023)
Filippo Giancotti (1958–2023)
The world of cancer research has suffered the loss of a gifted cancer scientist, devoted mentor, caring s...
Aiming at different targets for immunotherapy
Identifying different ways to stimulate the anti-tumor immune response is essential to enrich the immunotherapy arsenal wi...
Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia
Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia
Cachexia is a major cause of morbidity and mortality in individuals with cancer and is characterized by weight loss due to...
Harnessing progress in radiotherapy for global cancer control
Harnessing progress in radiotherapy for global cancer control
The pace of technological innovation over the past three decades has transformed the field of radiotherapy into one of the...
Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer
Acetate acts as a metabolic immunomodulator by bolstering T-cell effector function and potentiating antitumor immunity in breast cancer
Acetate metabolism is an important metabolic pathway in many cancers and is controlled by acetyl-CoA synthetase 2 (ACSS2),...
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma
The PDCD1-encoded immune checkpoint receptor PD-1 is a key tumor suppressor in T cells that is recurrently inactivated in ...
Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants
Vepafestinib: a RET-selective inhibitor with enhanced CNS penetrance targets therapy-resistant mutants
We sought to develop a pharmacologically advanced inhibitor of the oncoprotein RET. Vepafestinib potently inhibited on-tar...
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer
We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian ca...
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
RET receptor tyrosine kinase is activated in various cancers (lung, thyroid, colon and pancreatic, among others) through o...
Load More
format_indent_increase